---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-081942"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:11:01.485087+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics appoints Tim Van Hauwermeiren, argenx CEO, to Board

## Summary
- Appointment effective July 5, 2024; term expires at 2027 annual meeting.
- Standard director comp: $40k annual cash, initial option for 36,000 shares, annual option for 18,000 shares.
- Van Hauwermeiren is co-founder and CEO of argenx; built company to ~$25B market cap.
- No arrangements or family relationships with Lexeo officers; standard indemnification agreement.
- Appointed as independent, non-executive director.

## SEC filing metadata
- accession: 0000950170-24-081942
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/0000950170-24-081942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/lxeo-20240708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-081942
- JSON: https://secwatch.observer/filing/0000950170-24-081942.json
- Plain text: https://secwatch.observer/filing/0000950170-24-081942.txt

## Key facts
- Executive change
  Tim Van Hauwermeiren was appointed as Director at Lexeo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On July 5, 2024 (the “Appointment Date”), Tim Van Hauwermeiren was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/0000950170-24-081942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.